The influence of cigarette smoke on the polymorphism of matrix metalloprotease (MMP2) in asthmatic patients Source: Annual Congress 2011 - New mechanisms in airway disease Year: 2011
Interaction of matrix metalloproteinases with pulmonary pollutants Source: Eur Respir J 2012; 39: 1021-1032 Year: 2012
Determination of lung function changes, sputum neutrophilia and metalloproteinases (MMPs) activities in workers at risk of repeated accidental inhalations of chlorine Source: Eur Respir J 2002; 20: Suppl. 38, 603s Year: 2002
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Genotype and phenotype in susceptibility to coal workers' pneumoconiosis. The use of cytokines in perspective Source: Eur Respir J 2001; 18: 127S-133S Year: 2001
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Matrix metalloproteinase 12 (MMP-12) expression in human monocyte-derived macrophages is enhanced by exposure to cigarette smoke and is resistant to suppression by dexamethasone Source: Eur Respir J 2004; 24: Suppl. 48, 107s Year: 2004
Production of matrix metalloprotease-9 (MMP-9) by alveolar macrophages (AMs) from smokers: effect of corticosteroids and phosphodiesterase inhibition Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The genetic polymorphism of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011
Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD. Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
Analysis of GST and TNF-a genes polymorphism association with risk development of asbestosis in workers exposed to chrysotile asbest. Source: Virtual Congress 2021 – Chronic airway, interstitial, pleural and neoplastic diseases Year: 2021
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Effects of keratinocyte growth factor (KGF) on matrix metalloproteinases (MMPs) & tissue inhibitors of metalloproteinases (TIMPs) mRNA levels in emphysematous rats lungs Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Matrix metalloproteinases in COPD Source: Eur Respir J 2012; 39: 197-209 Year: 2012
Matrix metalloproteinases in COPD Source: Eur Respir J 2011; 39: 197-209 Year: 2012
Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002